Document is current
Any future updates will be listed below
-
Authors
Giacani, Lorenzo
Bradshaw, Catriona S.
Muzny, Christina A.
Graves, Keonte J.
Pasricha, Shivani
Jordan, Stephen J.
Allan-Blitz, Lao-Tzu
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases,United States (R56AI175016, R01AI176999, K23AI182453)
Australian Research Council Industrial Transformation Research Hub Grant (IH190100021, IH190100021)
National Health and Medical Research Council (APP1173361)
National Institute of Allergy and Infectious Diseases,United States, (R01AI177002)
- License Information
-
More Information
Article History
Accepted: 7 January 2025
First Online: 25 January 2025
Declarations
:
: C.S.B. and S.P. have received funds from SpeeDx Inc., to study resistance-guided therapy. C.A.M has received grants to her institution from Abbott, BioNTech, Gilead, Lupin, and Visby. She also reports honorarium and/or consulting fees from Cepheid, BioNTech, bioMérieux, Visby, Elsevier, Merck Manuals, UpToDate, and Abbott. S.J.J. has received consulting fees from Preventx Inc. L.A.B. has received honorarium from Elsevier and UpToDate. The remaining authors have no conflicts of interest to disclose.
